
|Videos|July 7, 2017
Dr. Arend on the PORTEC-3 Trial for Endometrial Cancer
Author(s)Rebecca C. Arend, MD
Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses the PORTEC-3 trial for patients with endometrial cancer.
Advertisement
Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses the PORTEC-3 trial for patients with endometrial cancer.
This trial included patients with high/intermediate risk who received either radiation or radiation plus chemotherapy. According to Arend, if a patient has stage 3 endometrial cancer they should receive chemotherapy.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5



































